MAPT and Cognitive impairment: Notably, pharmacological inhibition of AEP with compound #11, a small-molecule inhibitor, reduces Tau and APP cleavage, alleviating AD-related pathology and cognitive deficits in Tau P301S and 5XFAD mice [21].